Email this article Analysis of drugs assortment and their consumption in older age patients diagnosed with COVID-19
- Authors: Gladunova E.P.1, Shirobokov Y.E.1, Borodulina E.A.1
-
Affiliations:
- Samara State Medical University
- Issue: Vol 21, No 5-6 (2021)
- Pages: 161-166
- Section: Pharmacy
- URL: https://journals.rcsi.science/2410-3764/article/view/105876
- DOI: https://doi.org/10.55531/2072-2354.2021.21.3.161-166
- ID: 105876
Cite item
Full Text
Abstract
BACKGROUND: To identify the features of coronavirus infection (COVID-19) treatment in older working age individuals the analysis of the drugs assortment and treatment schemes used in COVID hospitals in Samara was carried out.
AIM: The purpose of the research was to study the drugs used to treat senior patients in the hospitals of Samara Region, to identify the main drugs, to form a range of medical preparations and to predict the volume of their consumption.
MATERIALS AND METHODS: The study carried out a retrospective analysis of 218 cases of patients with coronavirus infection treated in Samara medical institutions from May till July 2020.
RESULTS: The main symptoms, comorbidities, the average duration of symptom manifestation prior to admission in both groups of patients, as well as the essential drugs used to treat the infection have been identified.
CONCLUSIONS: The analysis of the studied drugs used for the treatment of coronavirus infections should form the basis for the formation of an optimal range of drugs, forecasting the need for drugs in the light of scientifical pharmacoeconomic approaches.
Full Text
##article.viewOnOriginalSite##About the authors
Elena P. Gladunova
Samara State Medical University
Author for correspondence.
Email: epg87@mail.ru
Doctor of Pharmaceutical Sciences, Associate Professor, Professor of the Department of Management and Economics of Pharmacy
Russian Federation, SamaraYaroslav E. Shirobokov
Samara State Medical University
Email: yshirobokov@gmail.com
Postgraduate student, Department of Management and Economics of Pharmacy
Russian Federation, SamaraElena A. Borodulina
Samara State Medical University
Email: borodulinbe@yandex.ru
Doctor of Medical Sciences, Professor, Head of the Department of Phthisiology and Pulmonology
Russian Federation, SamaraReferences
- Shamsheva OV. New coronavirus COVID-19 (SARS-CoV-2). Children Infections. 2020;19(1):5–6. (In Russ.). doi: 10.22627/2072-8107-2020-19-1-5-6
- Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi: 10.1183/13993003.00547-2020
- Jordan RE, Adab P, Cheng KK. COVID-19: risk factors for severe disease and death. BMJ. 2020;368:m1198. doi: 10.1136/bmj.m1198
- Raoult D, Zumla A, Locatelli F, et al. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress. 2020;4(4):66–75. doi: 10.15698/cst2020.04.216
- Yanez ND, Weiss NS, Romand JA, et al. COVID-19 mortality risk for older men and women. BMC Public Health. 2020;20(1):1742. doi: 10.1186/s12889-020-09826-8
Supplementary files
